1047 related articles for article (PubMed ID: 7554973)
1. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
2. Changes in androgens during treatment with four low-dose contraceptives.
Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
[TBL] [Abstract][Full Text] [Related]
3. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D; Smith S; Zacur H
Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
[TBL] [Abstract][Full Text] [Related]
4. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
Coenen CM; Thomas CM; Borm GF; Rolland R
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
[TBL] [Abstract][Full Text] [Related]
6. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
7. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
Lemay A; Dewailly SD; Grenier R; Huard J
J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
[TBL] [Abstract][Full Text] [Related]
10. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
11. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
Aden U; Jung-Hoffmann C; Kuhl H
Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261
[TBL] [Abstract][Full Text] [Related]
12. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
[TBL] [Abstract][Full Text] [Related]
13. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen.
Sobbrio GA; Granata A; Granese D; D'Arrigo F; Panacea A; Nicita R; Pullè C; Trimarchi F
Clin Exp Obstet Gynecol; 1991; 18(1):43-5. PubMed ID: 1829029
[TBL] [Abstract][Full Text] [Related]
14. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
[TBL] [Abstract][Full Text] [Related]
15. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
Janaud A; Rouffy J; Upmalis D; Dain MP
Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555
[TBL] [Abstract][Full Text] [Related]
16. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
17. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives.
Nielsen CH; Poulsen HK; Teisner B; Thorsen P; Hau J; Westergaard JG
Eur J Obstet Gynecol Reprod Biol; 1993 Sep; 51(1):63-71. PubMed ID: 7506680
[TBL] [Abstract][Full Text] [Related]
18. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
Anderson FD
Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
[TBL] [Abstract][Full Text] [Related]
19. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
Palatsi R; Reinilä M; Kivinén S
Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
[TBL] [Abstract][Full Text] [Related]
20. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]